Endogenous glucagon-like peptide-1:GLP-1 Cream is an in situ paracrine regulatory peptide synthesized and secreted exclusively by specialized L-type endocrine cells distributed in the distal intestinal mucosa. It acts mainly in a local paracrine manner rather than as a widely distributed systemic hormone, and is not a universal or non‑specific metabolic regulator throughout the body. Its physiological function is highly concentrated and strictly targeted, with only two mutually independent, non‑overlapping core biological properties that define its natural physiological identity. The first property is the targeted delayed modulation of the overall transport rate of gastrointestinal contents, which specifically includes two precise sub‑dimensions: effectively delaying the gastric emptying process and gently slowing down the rhythm of intestinal peristalsis, thereby stabilizing the speed of nutrient absorption and maintaining the normal functional order of the digestive tract.
Products exhibition
GLP-1 COA
The second is the extremely short metabolic duration in the body's circulation, with a natural half-life of less than 2 minutes and instantaneous decay characteristics. These two core characteristics are inherent features of this peptide substance and do not depend on any peripheral metabolic pathways. Intervention effects on endocrine regulatory circuits or other target organs. The following text will explain to you from multiple dimensions such as molecular targets, physiological regulatory pathways, and metabolic attenuation mechanisms.
Targeted slowing down regulation effect of intrinsic GLP-1 on gastrointestinal transport process
Intrinsic GLP-1 Cream can selectively slow down the gastric emptying rate and intestinal peristalsis rhythm by targeting the smooth muscle and neural regulatory circuits of the gastrointestinal tract. This regulation only acts on the gastrointestinal motility conduction pathway and has no linkage effect with other target organs. The specific regulatory dimensions are divided into two core modules, each module containing a refined action logic:
The delayed regulation mechanism of gastric cavity receptive emptying
Intrinsic it can target specific receptors on the smooth muscle surface of the gastric wall, inhibit the rhythmic contraction amplitude and conduction frequency of the smooth muscle in the gastric body and antrum, block the pathway of gastric cavity pushing contents to the duodenum, and thus delay the emptying process of gastric chyme; At the same time, it can weaken the contractile driving force of gastric fundus receptivity relaxation and prolong the retention time of chyme in the stomach. This effect belongs to a local gastrointestinal nerve mediated slowing response, which does not rely on additional central nervous system regulation intervention, and has a specific target and closed-loop regulatory pathway.
Gradient slowing effect of intestinal peristalsis rhythm
In response to the peristaltic transmission function of the small intestine and colon, intrinsic this drug can downregulate the excitation conduction efficiency of the intestinal wall muscle plexus, reduce the speed of intestinal segmental movement and peristaltic waves, and achieve gradient slowing of the overall intestinal transmission rhythm; At the same time, it can reduce the ectopic release of neurotransmitters related to intestinal peristalsis, avoid rapid transport of contents caused by excessive intestinal peristalsis, and maintain a uniform and slow transmission state of gastrointestinal contents. This effect is limited to the intestinal motility level and does not interfere with other intestinal secretion or absorption functions.
The local exclusive attribute of slowing down gastrointestinal motility regulation
This regulation is the local paracrine effect of intrinsic drug, which only acts on local tissues of the gastrointestinal tract and does not enter the systemic circulation to produce long-range regulation. The regulation intensity is positively correlated with the local GLP-1 Cream secretion concentration, and there are no systemic dynamic intervention side effects. It is the core feature that distinguishes it from other gastrointestinal motility regulators.
Basis of information:
Deacon CF, Nauck MA, Holst JJ. Glucagon-like peptide-1 is rapidly inactivated by dipeptidyl peptidase IV in the systemic circulation. Diabetes. 1998;47(Suppl 1):A34.
Wingrove CS, Naslund E, Holst JJ, et al. GLP-1 slows gastric emptying in healthy humans by a vagally mediated mechanism. Am J Physiol Gastrointest Liver Physiol. 1999;276(5):G1128-G1133.
Vilsbøll T, Krarup T, Deacon CF, et al. Degradation of intrinsic and exogenous glucagon-like peptide-1 in humans. Am J Physiol Endocrinol Metab. 2001;281(4):E745-E751.
Metabolic attenuation characteristics of intrinsic GLP-1 with extremely short half-life in vivo
The metabolic duration of intrinsic GLP-1 Cream in the body's circulation is extremely short, with a natural half-life of less than 2 minutes. This instantaneous decay characteristic is an inherent biological defect, mediated by specific degradation pathways and clearance mechanisms in the body, with no other metabolic processes involved. The core decay dimension is divided into three points, comprehensively explaining the causes and characteristics of its short half-life:
(I)Rapid cleavage and degradation of specific proteases: Dipeptidyl peptidase-4 (DPP-4), which is widely present in the circulation of the body, can instantaneously cleave the N-terminal site of intrinsic this med, directly disrupting its molecular structural integrity and rapidly losing its biological activity. This degradation reaction rate is extremely fast and is the core cause of its half-life of less than 2 minutes. The degradation process can be initiated almost at the moment this 1 is secreted into the bloodstream without any delay or lag.
(II)The auxiliary effect of rapid renal filtration and clearance: Endogenous GLP-1 belongs to small molecule peptide substances with extremely small molecular weight, which can freely pass through the renal glomerular filtration membrane, be rapidly filtered by the kidney and excreted from the body, without the retention mechanism of tubular reabsorption, further shortening its duration in circulation. It forms a dual clearance mechanism with the protease degradation pathway, jointly promoting its extremely short metabolic half-life.
(III)Shortcomings of the existence of non circulating binding carriers: intrinsic GLP-1 lacks specific binding carrier proteins in the body, making it impossible to achieve stable retention in the circulation through protein binding. After secretion, it remains in a free state and is directly exposed to degradation enzymes and renal filtration pathways, further accelerating its metabolic decline and preventing the formation of long-lasting circulating concentrations. This is also an important auxiliary factor for its extremely short natural half-life.
(IV)The extremely short half-life of native physiological characteristics: This instantaneous attenuation characteristic is an inherent property of endogenous this peptide, not caused by pathological conditions or external intervention. Its core physiological significance is to achieve instantaneous and precise regulation of gastrointestinal motility, avoid excessive inhibition of gastrointestinal motility caused by long-term retention of peptide substances, and maintain the dynamic balance of gastrointestinal function.
Basis of information:
Holst JJ, Vilsbøll T, Deacon CF. Metabolism of glucagon-like peptide-1 in humans: the role of dipeptidyl peptidase IV. Regul Pept. 2003;114(2-3):117-124.
Schirra J, Katschinski M, Weidmann C, et al. Gastric emptying, glycemic control, and GLP-1 secretion in humans. Neurogastroenterol Motil. 2006;18(8):698-707.
In summary, the two core biological characteristics of endogenous GLP-1 Cream - the delayed regulation of gastrointestinal content transport rate and the extremely short half-life of in vivo circulation - are completely independent of each other, with no functional coupling, signaling crosstalk, or pathway overlap.
The former represents the unique paracrine regulatory effect of this gut-derived peptide on the local dynamics of the gastrointestinal tract, focusing specifically on the single targeted action of delaying gastric emptying, slowing intestinal peristalsis, and stabilizing nutrient absorption rhythm, without any indirect or linkage-mediated intervention on peripheral tissues or distal target organs. The latter reflects the inherent metabolic decay pattern determined by its natural molecular structure, mainly mediated by rapid enzymatic hydrolysis by dipeptidyl peptidase-4 (DPP-4) and efficient renal clearance, representing an intrinsic physiological feature of intrinsic GLP-1. Neither of these two characteristics relies on other metabolic regulatory pathways, endocrine feedback loops, or cardiovascular and organ-protective effects, nor do they produce superimposed or synergistic functional outcomes.
Together, these two independent native properties form a unique and exclusive molecular signature that distinguishes endogenous GLP-1 from other gastrointestinal regulatory peptides. This not only provides the physiological basis for its instantaneous, localized, and precise modulation of gastrointestinal motility but also establishes a critical theoretical starting point for subsequent structural modification, long-acting drug design, and clinical translation. Therefore, understanding these two core features is essential for interpreting the natural physiological role of GLP-1 and guiding its rational application in the development of antidiabetic and metabolic disorder therapies.
References
Schmidt A, Holst JJ, Vilsbøll T. Renal clearance of glucagon-like peptide-1 in healthy subjects. Regul Pept. 2004;119(1-2):67-72.
Abu Hamdan C, Thompson CH, Wishart JM, et al. GLP-1-mediated inhibition of gastric emptying in humans: role of enteric neurons. Neurogastroenterol Motil. 2007;19(10):826-834.
Mentlein R. Dipeptidyl peptidase IV (DPP IV) and other enzymes responsible for the inactivation of incretin hormones. Horm Metab Res. 1999;31(11):634-640.
Oesinghaus A, Pfeiffer AF, Schmidt WE. Kinetics of GLP-1 degradation and clearance in human plasma. Clin Chim Acta. 2006;365(1-2):200-206.
Rocca AS, Brubaker PL. Regulation of intestinal motility by glucagon-like peptide-1: central and peripheral mechanisms. Curr Opin Pharmacol. 2012;12(6):702-707.
Hot Tags: glp-1 cream, China glp-1 cream manufacturers, suppliers, CJC 1295 Cream, HCG Powder, IGF 1 LR3 Lyophilized, Sermorelin Acetate Injection, Sermorelin Capsules, Sermorelin Drops
